235 related articles for article (PubMed ID: 37910614)
1. RANKL/RANK is required for cytokine-induced beta cell death; osteoprotegerin, a RANKL inhibitor, reverses rodent type 1 diabetes.
Kondegowda NG; Filipowska J; Do JS; Leon-Rivera N; Li R; Hampton R; Ogyaadu S; Levister C; Penninger JM; Reijonen H; Levy CJ; Vasavada RC
Sci Adv; 2023 Nov; 9(44):eadf5238. PubMed ID: 37910614
[TBL] [Abstract][Full Text] [Related]
2. Osteoprotegerin and Denosumab Stimulate Human Beta Cell Proliferation through Inhibition of the Receptor Activator of NF-κB Ligand Pathway.
Kondegowda NG; Fenutria R; Pollack IR; Orthofer M; Garcia-Ocaña A; Penninger JM; Vasavada RC
Cell Metab; 2015 Jul; 22(1):77-85. PubMed ID: 26094891
[TBL] [Abstract][Full Text] [Related]
3. Denosumab Attenuates Glucolipotoxicity-Induced β-Cell Dysfunction and Apoptosis by Attenuating RANK/RANKL Signals.
Lin SC; Tsou SH; Kuo CY; Chen WL; Wu KW; Lin CL; Huang CN
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373436
[TBL] [Abstract][Full Text] [Related]
4. Updates on the role of receptor activator of nuclear factor κB/receptor activator of nuclear factor κB ligand/osteoprotegerin pathway in breast cancer risk and treatment.
Bayer CM; Beckmann MW; Fasching PA
Curr Opin Obstet Gynecol; 2017 Feb; 29(1):4-11. PubMed ID: 28002265
[TBL] [Abstract][Full Text] [Related]
5. Receptor activator of nuclear factor-κB ligand (RANKL) protects against hepatic ischemia/reperfusion injury in mice.
Sakai N; Van Sweringen HL; Schuster R; Blanchard J; Burns JM; Tevar AD; Edwards MJ; Lentsch AB
Hepatology; 2012 Mar; 55(3):888-97. PubMed ID: 22031462
[TBL] [Abstract][Full Text] [Related]
6. Discovery of the RANKL/RANK/OPG system.
Yasuda H
J Bone Miner Metab; 2021 Jan; 39(1):2-11. PubMed ID: 33389131
[TBL] [Abstract][Full Text] [Related]
7. RANKL targeted peptides inhibit osteoclastogenesis and attenuate adjuvant induced arthritis by inhibiting NF-κB activation and down regulating inflammatory cytokines.
Naidu VG; Dinesh Babu KR; Thwin MM; Satish RL; Kumar PV; Gopalakrishnakone P
Chem Biol Interact; 2013 Apr; 203(2):467-79. PubMed ID: 23333834
[TBL] [Abstract][Full Text] [Related]
8. Expression of the RANK/RANKL/OPG system in the human intervertebral disc: implication for the pathogenesis of intervertebral disc degeneration.
Sano T; Akeda K; Yamada J; Takegami N; Sudo T; Sudo A
BMC Musculoskelet Disord; 2019 May; 20(1):225. PubMed ID: 31101043
[TBL] [Abstract][Full Text] [Related]
9. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
[TBL] [Abstract][Full Text] [Related]
10. Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss.
Trouvin AP; Goëb V
Clin Interv Aging; 2010 Nov; 5():345-54. PubMed ID: 21228900
[TBL] [Abstract][Full Text] [Related]
11. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives.
Infante M; Fabi A; Cognetti F; Gorini S; Caprio M; Fabbri A
J Exp Clin Cancer Res; 2019 Jan; 38(1):12. PubMed ID: 30621730
[TBL] [Abstract][Full Text] [Related]
12. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab.
Lacey DL; Boyle WJ; Simonet WS; Kostenuik PJ; Dougall WC; Sullivan JK; San Martin J; Dansey R
Nat Rev Drug Discov; 2012 May; 11(5):401-19. PubMed ID: 22543469
[TBL] [Abstract][Full Text] [Related]
13. OPG/RANKL/RANK axis is a critical inflammatory signaling system in ischemic brain in mice.
Shimamura M; Nakagami H; Osako MK; Kurinami H; Koriyama H; Zhengda P; Tomioka H; Tenma A; Wakayama K; Morishita R
Proc Natl Acad Sci U S A; 2014 Jun; 111(22):8191-6. PubMed ID: 24847069
[TBL] [Abstract][Full Text] [Related]
14. Osteoprotegerin/Receptor Activator of Nuclear Factor-Kappa B Ligand/Receptor Activator of Nuclear Factor-Kappa B Axis in Obesity, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease.
Vachliotis ID; Polyzos SA
Curr Obes Rep; 2023 Jun; 12(2):147-162. PubMed ID: 37208545
[TBL] [Abstract][Full Text] [Related]
15. Expression and Distribution of Receptor Activator of Nuclear Factor Kappa B, Receptor Activator of Nuclear Factor Kappa B Ligand, and Osteoprotegerin in Periradicular Cysts.
Armada L; Marotta Pdos S; Pires FR; Siqueira JF
J Endod; 2015 Aug; 41(8):1281-7. PubMed ID: 25956608
[TBL] [Abstract][Full Text] [Related]
16. S-amlodipine improves endothelial dysfunction via the RANK/RANKL/OPG system by regulating microRNA-155 in hypertension.
Yang J; Si D; Zhao Y; He C; Yang P
Biomed Pharmacother; 2019 Jun; 114():108799. PubMed ID: 30951948
[TBL] [Abstract][Full Text] [Related]
17. RANKL Impairs the TLR4 Pathway by Increasing TRAF6 and RANK Interaction in Macrophages.
Mota RF; Cavalcanti de Araújo PH; Cezine MER; Matsuo FS; Metzner RJM; Oliveira de Biagi Junior CA; Peronni KC; Hayashi H; Shimamura M; Nakagami H; Osako MK
Biomed Res Int; 2022; 2022():7740079. PubMed ID: 35463988
[TBL] [Abstract][Full Text] [Related]
18. Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6.
Mizukami J; Takaesu G; Akatsuka H; Sakurai H; Ninomiya-Tsuji J; Matsumoto K; Sakurai N
Mol Cell Biol; 2002 Feb; 22(4):992-1000. PubMed ID: 11809792
[TBL] [Abstract][Full Text] [Related]
19. The osteoprotegerin/receptor activator of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage.
Komuro H; Olee T; Kühn K; Quach J; Brinson DC; Shikhman A; Valbracht J; Creighton-Achermann L; Lotz M
Arthritis Rheum; 2001 Dec; 44(12):2768-76. PubMed ID: 11762937
[TBL] [Abstract][Full Text] [Related]
20. Repurposing an Osteoporosis Drug for β Cell Regeneration in Diabetic Patients.
Schmitz F; Roscioni S; Lickert H
Cell Metab; 2015 Jul; 22(1):58-9. PubMed ID: 26094892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
